Mineralys' lorundrostat gets a Phase 2 win in certain patients with hypertension
Mineralys Therapeutics said Tuesday that its blood pressure med lorundrostat has succeeded in a Phase 2 trial in subjects with hypertension and comorbid chronic kidney disease (CKD). The data will be added to a planned ...
Mineralys Therapeutics said Tuesday that its blood pressure med lorundrostat has succeeded in a Phase 2 trial in subjects with hypertension and comorbid chronic kidney disease (CKD). The data will be added to a planned ...
